NEOSTIGMINE METHYLSULFATE injection

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

NEOSTIGMINE METHYLSULFATE (UNII: 98IMH7M386) (NEOSTIGMINE - UNII:3982TWQ96G)

Available from:

Gland Pharma Limited

Administration route:

INTRAVENOUS

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Neostigmine Methylsulfate Injection is a cholinesterase inhibitor indicated for the reversal of the effects of non­-depolarizing neuromuscular blocking agents after surgery.  Neostigmine Methylsulfate Injection is contraindicated in patients with:        • known hypersensitivity to neostigmine methylsulfate (known hypersensitivity reactions have included urticaria, angioedema, erythema multiforme, generalized rash, facial swelling, peripheral edema, pyrexia, flushing, hypotension, bronchospasm, bradycardia and anaphylaxis).         • peritonitis or mechanical obstruction of the intestinal or urinary tract. Risk Summary There are no adequate or well-controlled studies of Neostigmine Methylsulfate Injection in pregnant women. It is not known whether Neostigmine Methylsulfate Injection can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. The incidence of malformations in human pregnancies has not been established for neostigmine as the data are limited. All preg

Product summary:

Neostigmine Methylsulfate Injection, USP is a clear, colorless solution and is available in multi-dose USP Type-I clear glass tubular vials in the following package sizes: The vial stopper is not made with natural rubber latex. Neostigmine Methylsulfate Injection, USP should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (see USP Controlled Room Temperature). Protect from light. Store in carton until time of use. Manufactured by: Gland Pharma Limited Pashamylaram Hyderabad - 502 307, INDIA Revised: 02/2021

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

NEOSTIGMINE METHYLSULFATE - NEOSTIGMINE METHYLSULFATE INJECTION
GLAND PHARMA LIMITED
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
NEOSTIGMINE
METHYLSULFATE INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR
NEOSTIGMINE METHYLSULFATE INJECTION.
NEOSTIGMINE METHYLSULFATE INJECTION,
FOR INTRAVENOUS USE
INITIAL U.S. APPROVAL: 1939
INDICATIONS AND USAGE
Neostigmine Methylsulfate Injection, a cholinesterase inhibitor, is
indicated for the reversal of the effects of
non-depolarizing neuromuscular blocking agents (NMBAs) after surgery
(1).
DOSAGE AND ADMINISTRATION
• Should be administered by trained healthcare providers (2.1)
• Peripheral nerve stimulator and monitoring for twitch responses
should be used to determine when
Neostigmine Methylsulfate Injection should be initiated and if
additional doses are needed (2.2)
• For reversal of NMBAs with shorter half-lives, when first twitch
response is substantially greater than
10% of baseline, or when a second twitch is present: 0.03 MG/KG BY
INTRAVENOUS ROUTE (2.2)
• For reversal of NMBAs with longer half-lives or when first twitch
response is close to 10% of baseline:
0.07 MG/KG BY INTRAVENOUS ROUTE (2.2)
• Maximum total dosage is 0.07 mg/kg or up to a total of 5 mg
(whichever is less) (2.2)
• An anticholinergic agent, e.g., atropine sulfate or
glycopyrrolate, should be administered prior to or
concomitantly with Neostigmine Methylsulfate Injection (2.4)
DOSAGE FORMS AND STRENGTHS
Injection: 0.5 mg/mL and 1 mg/mL in 10 mL multiple-dose vials (3)
CONTRAINDICATIONS
• Hypersensitivity to neostigmine (4)
• Peritonitis or mechanical obstruction of the intestinal or urinary
tract (4)
WARNINGS AND PRECAUTIONS
• Bradycardia: Atropine or glycopyrrolate should be administered
prior to Neostigmine Methylsulfate
Injection to lessen risk of bradycardia. (5.1)
• Serious Reactions with Coexisting Conditions: Use with caution in
patients with coronary artery disease,
cardiac arrhy